{"id":"placebo-to-salmeterol-fluticasone","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Cough"},{"rate":"5-10%","effect":"Oral thrush"},{"rate":"5-10%","effect":"Bronchitis"},{"rate":"5-10%","effect":"Sinusitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Salmeterol works by binding to and activating the beta2-adrenergic receptor, leading to bronchodilation and improved lung function. Fluticasone, on the other hand, exerts its effects by inhibiting the release of pro-inflammatory cytokines and mediators, thereby reducing inflammation in the airways.","oneSentence":"Salmeterol is a long-acting beta2-adrenergic receptor agonist, while fluticasone is a corticosteroid that inhibits inflammatory processes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:03.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT06040268","phase":"PHASE1, PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":"Altitude Edema","enrollment":60},{"nctId":"NCT04655508","phase":"PHASE3","title":"Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-21","conditions":"Stem Cell Transplant Complications, Respiratory Disease, Bronchiolitis Obliterans","enrollment":35},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT00127166","phase":"PHASE3","title":"Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Exercise Induced Asthma","enrollment":154},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT03756883","phase":"PHASE3","title":"Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-12-03","conditions":"Asthma","enrollment":999},{"nctId":"NCT03207243","phase":"PHASE2","title":"Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Asthma","enrollment":165},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT02496715","phase":"PHASE3","title":"Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics","status":"WITHDRAWN","sponsor":"Actavis Inc.","startDate":"2015-09","conditions":"Asthma","enrollment":""},{"nctId":"NCT00731770","phase":"PHASE4","title":"Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2009-01","conditions":"COPD","enrollment":10},{"nctId":"NCT01494610","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01696214","phase":"PHASE4","title":"A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2012-10","conditions":"Asthma","enrollment":20},{"nctId":"NCT03562923","phase":"PHASE3","title":"A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50","status":"UNKNOWN","sponsor":"Amneal Ireland Limited","startDate":"2018-10","conditions":"Asthma","enrollment":1204},{"nctId":"NCT01706328","phase":"PHASE3","title":"A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":828},{"nctId":"NCT01323621","phase":"PHASE3","title":"Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-18","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":512},{"nctId":"NCT01772134","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":617},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT01879410","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":700},{"nctId":"NCT00315744","phase":"PHASE4","title":"Viapaed Study In Children And Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-04","conditions":"Asthma","enrollment":285},{"nctId":"NCT01822899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":717},{"nctId":"NCT01978145","phase":"PHASE3","title":"A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":665},{"nctId":"NCT00642148","phase":"PHASE2","title":"A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":306},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT01312961","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-03","conditions":"Asthma","enrollment":104},{"nctId":"NCT02416180","phase":"PHASE4","title":"Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-18","conditions":"Asthma","enrollment":111},{"nctId":"NCT01978119","phase":"PHASE3","title":"A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-06","conditions":"Asthma","enrollment":124},{"nctId":"NCT01757015","phase":"PHASE3","title":"Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01156792","phase":"PHASE2","title":"Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Asthma","enrollment":162},{"nctId":"NCT01772147","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":608},{"nctId":"NCT00857766","phase":"PHASE4","title":"A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":249},{"nctId":"NCT00358358","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease Endpoints Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":163},{"nctId":"NCT00268216","phase":"PHASE3","title":"Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6228},{"nctId":"NCT01147848","phase":"PHASE3","title":"HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06","conditions":"Asthma","enrollment":810},{"nctId":"NCT00503009","phase":"PHASE4","title":"Study Of RV-39 In Patients Who Also Have Asthma","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Asthma","enrollment":16},{"nctId":"NCT00441441","phase":"PHASE3","title":"A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Asthma","enrollment":351},{"nctId":"NCT00517634","phase":"PHASE4","title":"Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Asthma","enrollment":23},{"nctId":"NCT00163358","phase":"PHASE3","title":"Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-09","conditions":"Asthma","enrollment":630},{"nctId":"NCT01248975","phase":"PHASE2","title":"Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Asthma","enrollment":145},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT01762800","phase":"PHASE4","title":"Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":407},{"nctId":"NCT00268177","phase":"PHASE3","title":"Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":130},{"nctId":"NCT00920543","phase":"PHASE4","title":"GSK BHR Study (Sont)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-02","conditions":"Asthma","enrollment":464},{"nctId":"NCT01324362","phase":"PHASE4","title":"GSK BHR Study (Sont - Second Study)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Asthma","enrollment":446},{"nctId":"NCT00385463","phase":"NA","title":"Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo","status":"WITHDRAWN","sponsor":"Creighton University","startDate":"2006-04","conditions":"Asthma, Seasonal Allergic Rhinitis","enrollment":""},{"nctId":"NCT01969721","phase":"PHASE3","title":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":229},{"nctId":"NCT00741767","phase":"NA","title":"The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2008-08","conditions":"Chronic Obstructive Pulmonary Disease, Sleep Disorders","enrollment":""},{"nctId":"NCT01709903","phase":"PHASE3","title":"A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":744},{"nctId":"NCT02218762","phase":"PHASE1","title":"A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2014-10","conditions":"Asthma","enrollment":""},{"nctId":"NCT00975195","phase":"PHASE4","title":"Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2488},{"nctId":"NCT01513460","phase":"PHASE3","title":"Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":773},{"nctId":"NCT02270424","phase":"PHASE3","title":"Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe / Very Severe COPD","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2014-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":564},{"nctId":"NCT01209715","phase":"PHASE2","title":"Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2010-10","conditions":"COPD","enrollment":""},{"nctId":"NCT01868009","phase":"PHASE3","title":"DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":287},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT01315249","phase":"PHASE3","title":"QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":523},{"nctId":"NCT01321463","phase":"PHASE2","title":"Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":377},{"nctId":"NCT00556673","phase":"PHASE2","title":"Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Asthma","enrollment":31},{"nctId":"NCT00557440","phase":"PHASE2","title":"Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Asthma","enrollment":37},{"nctId":"NCT00559312","phase":"NA","title":"The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2007-12","conditions":"COPD","enrollment":18},{"nctId":"NCT00314574","phase":"PHASE3","title":"A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Asthma","enrollment":850},{"nctId":"NCT00669617","phase":"PHASE3","title":"Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":89},{"nctId":"NCT00655616","phase":"NA","title":"Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2007-08","conditions":"Asthma","enrollment":64},{"nctId":"NCT00646009","phase":"PHASE3","title":"Symbicort Onset of Action 2","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-03","conditions":"Asthma","enrollment":48},{"nctId":"NCT00403286","phase":"PHASE2","title":"A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457},{"nctId":"NCT00646620","phase":"PHASE3","title":"Symbicort Onset of Action 1","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Salmeterol/fluticasone","genericName":"Placebo to Salmeterol/fluticasone","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Salmeterol is a long-acting beta2-adrenergic receptor agonist, while fluticasone is a corticosteroid that inhibits inflammatory processes. Used for Chronic obstructive pulmonary disease (COPD), Asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}